Trial Profile
Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 01 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 05 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.